 WATERTOWN, Mass., Feb. 03, 2021 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Ashwin Gollerkeri, MD, as Senior Vice President, Head of Development, and Kevin Dushney, as Vice President, Information Technology, as well as the promotion of Karen Martin, JD, PhD to Vice President, Head of Legal. 